EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

DNA Repair Pathways as Determinants of PARP Inhibitor Resistance and Therapeutic Targets in Cancer

Kousalya Lavudi iD, Malavika Sunita Renjith, Charan Pithana Sai Venkata Vijay iD, Rekha Rani Kokkanti iD, Prashant Pandey iD, Srikanth Ponneganti

International Journal of Molecular Sciences · 01.11.2026 · 27 (21) · 9814

DOI: 10.3390/ijms27219814 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.11.2026. Verfasst von Kousalya Lavudi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, Neoplasms, DNA Repair. Die Arbeit nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment landscape for homologous recombination-deficient (HRD) cancers, particularly those harboring BRCA1/2 mutations, including breast, ovarian, prostate, and pancreatic cancers, by exploiting the synthetic lethality induced by HR deficiency (HRD) and utilizing HRD status as a predictive biomarker. Nevertheless, intrinsic as well as acquired resistance limits their long-term effectiveness. Resistance often develops as a result of several complex mechanisms including the restoration of homologous recombination (HR), stabilization of the replication fork, enhanced drug efflux, loss of PARP1 expression, epigenetic modifications, and changes in the DNA damage response signaling. BRCA1/2-mutant cells, deficient in HR, become reliant on alternative repair pathways like classical non-homologous end joining (c-NHEJ) and microhomology-mediated end joining (MMEJ). Emerging evidence indicates the importance of replication-induced gaps in single-stranded DNA (ssDNA) and alternative pathways of DNA repair in defining PARPi sensitivity and resistance. This review aims to provide a comprehensive analysis of the established and emerging molecular mechanisms of PARPi resistance, and compensatory DNA repair pathways such as MMEJ. In addition to highlighting resistance pathways, the review also discusses strategies focusing on targeting repair mechanisms and replication stress signaling by using novel drugs targeting DNA polymerase theta (POLQ). It subsequently discusses preclinical advancements and ongoing clinical trials. Through linking the molecular determinants of resistance to the translational status and limitations of the latest therapies, this review offers a comparative framework for understanding resistance mechanisms and strategies to restore PARPi sensitivity in cancers with HRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmNeoplasmsDNA RepairHumansAnimalsDNA End-Joining RepairMolecular Targeted TherapyDNA Damage

Stichwörter der Autor:innen

PARPihomologous recombinationmicrohomology-mediated end joiningnon-homologous end joiningtranslesion synthesis

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
  • Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
  • Department of Biotechnology, National Institute of Technology Warangal, Hanamkonda 506004, Telangana, India.
  • Bioclues.org, Kukatpally, Hyderabad 500072, Telangana, India.
  • School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar 751024, Odisha, India.
  • Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.

ORCID-Profile: Kousalya Lavudi, Charan Pithana Sai Venkata Vijay, Rekha Rani Kokkanti, Prashant Pandey

Zitieren

APA

Lavudi, K., Renjith, M. S., Pithana Sai Venkata Vijay, C., Kokkanti, R. R., Pandey, P., & Ponneganti, S. (2026). DNA Repair Pathways as Determinants of PARP Inhibitor Resistance and Therapeutic Targets in Cancer. International Journal of Molecular Sciences, 27(21), 9814. https://doi.org/10.3390/ijms27219814

Vancouver

Lavudi K, Renjith MS, Pithana Sai Venkata Vijay C, Kokkanti RR, Pandey P, Ponneganti S. DNA Repair Pathways as Determinants of PARP Inhibitor Resistance and Therapeutic Targets in Cancer. International Journal of Molecular Sciences. 2026;27(21):9814. doi:10.3390/ijms27219814

BibTeX
@article{Lavudi2026,
  author = {Lavudi, Kousalya and Renjith, Malavika Sunita and Pithana Sai Venkata Vijay, Charan and Kokkanti, Rekha Rani and Pandey, Prashant and Ponneganti, Srikanth},
  title = {DNA Repair Pathways as Determinants of PARP Inhibitor Resistance and Therapeutic Targets in Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9814},
  doi = {10.3390/ijms27219814}
}
Kostenlos starten →